AGGRESSIVE NON-HODGKIN LYMPHOMA
Clinical trials for AGGRESSIVE NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new AGGRESSIVE NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for AGGRESSIVE NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tame aggressive lymphoma
Disease control Recruiting nowThis early-stage trial tests whether adding the targeted drug polatuzumab vedotin (with or without another drug, glofitamab) to standard chemotherapy is safe and tolerable for people with untreated, fast-growing B-cell lymphomas. About 56 participants will receive the combination…
Matched conditions: AGGRESSIVE NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo attack on hard-to-treat lymphoma shows promise in early trial
Disease control Recruiting nowThis study tests whether giving a special immune cell treatment (CAR-T therapy) followed by two additional drugs (mosunetuzumab and polatuzumab) can shrink tumors in people with aggressive non-Hodgkin lymphoma that has returned or not responded to prior treatments. About 22 adult…
Matched conditions: AGGRESSIVE NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Lazaros Lekakis • Aim: Disease control
Last updated May 14, 2026 12:06 UTC